BOSTON– MoldCo, a clinician-led digital health platform focused on mold and environmental toxin care, announced it has raised $8 million in seed funding co-led by Cantos and Collaborative Fund. The round brings the company’s total funding to $11 million and will support expansion of its virtual clinic and efforts to standardize mold detox as routine preventive care.
MoldCo’s model combines affordable telehealth access, advanced lab testing, evidence-based treatments, and 24/7 care navigation. The company said it is addressing a “hidden health crisis,” noting that more than half of U.S. households show signs of mold, water damage or dampness, yet mold-related illness remains underdiagnosed. Patients often spend years and thousands of dollars seeking explanations for symptoms such as fatigue or inflammation that are frequently misattributed to other conditions.
“My own journey through the confusing and often dismissive landscape of conventional medicine while battling mold illness was frustrating and isolating,” said Ariana Thacker, founder and CEO of MoldCo. “It revealed a critical gap: individuals are suffering because the specialized knowledge needed to recognize and effectively treat these conditions is widely unavailable. MoldCo was born from that experience. By combining specialized clinical expertise with telehealth accessibility, we’re making evidence-based care available to everyone who needs it as quickly as possible, at a fraction of the current cost.”
Dr. Ritchie Shoemaker, a leading researcher in biotoxin illness and Chronic Inflammatory Response Syndrome (CIRS), said MoldCo is bringing decades of science into clinical practice. “The days of simply living with mold and biotoxin-related illness have been replaced by peer-reviewed treatment protocols, developed from nearly 30 years of research and evidence-based care, and now being made accessible through MoldCo,” he said.
Investors said MoldCo is building the infrastructure for a neglected area of health care. “The sheer scale of the Mold Toxicity crisis, hidden within the walls of our homes and workplaces and deeply impacting human health, represents exactly the kind of systemic, science-driven challenge Cantos exists to address,” said Amee Kapadia, partner at Cantos.
Andrew Montgomery, partner at Collaborative Fund, added: “We invest in companies creating a fundamentally better future, and MoldCo directly addresses the critical nexus of our living environments and our long-term health. Their intelligent, telehealth-first approach is precisely what’s needed to democratize access to this specialized care and empower individuals to break cycles of chronic illness linked to mold exposure.”
MoldCo estimates its treatments cost $150 to $300 per month, significantly less than traditional fragmented approaches that can run into the tens of thousands of dollars. Services include on-demand access to MoldCo-certified specialists, specialized biomarker testing starting at $99, prescription therapies shipped directly to patients, and dedicated care navigators.
